Improvement of vascular health in people with type 1 diabetes. Nutritional, Metabolic, Endocrine
Conditions
Interventions
The study will use a randomised, crossover design, in which participants will complete two 7-hour experimental conditions, each separated by at least 4 days. One condition will involve participants si
Sponsors
University of Birmingham
Eligibility
Sex/Gender
All
Age
18 Years to 66 Years
Inclusion criteria
Inclusion criteria: 1. Having been diagnosed with T1D for more than 3 years 2. Aged 18-66 years 3. Not currently meeting physical activity guidelines of > 150 min/week of moderate-intensity exercise or >75 min/week of high-intensity exercise 4. Are sedentary (normally spend more than 5h per day sitting or lying down) 5. Use a closed-loop insulin delivery system
Exclusion criteria
Exclusion criteria: 1. Pregnant or planning to become pregnant 2. 85 mmol/L) 5. Having a history of severe hypoglycaemia requiring third-party assistance within the last 3 months 6. Cold or flu within the last 2 weeks
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Peripheral vascular function, as measured by superficial femoral artery flow-mediated dilation at pre-intervention (0h) and post-intervention (7h) | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Peripheral blood flow as measured by superficial femoral artery blood flow and shear rate at pre-intervention (0h) and post-intervention (7h) 2. Cerebral blood flow as measured by common carotid artery and internal carotid artery blood flow at pre-intervention (0h) and post-intervention (7h) 3. Cerebral vascular function as measured by middle cerebral artery blood velocity and CO2 reactivity at pre-intervention (0h) and post-intervention (7h) 4. Blood pressure as measured using automated resting blood pressure measurement at pre-intervention (0h), 1.75h, 3.5h, 5.25h and post-intervention (7h) 5. Heart rate measured using continuous heart rate monitoring throughout the intervention 6. Markers of glycaemia as measured using a continuous glucose monitor time in range (3.9–10.0 mmol/L) measured via, mean glucose, % time in hypoglycaemia (13.9 mmol/L), glycaemic variability hypoglycaemia/hyperglycaemia episodes, area under the curve measured 7. Insulin dose as measured using an insulin log of a closed-loop insulin pump, the mean insulin dose of the intervention 8. Serum markers of vascular function as measured using endothelin 1 concentrations, vascular cellular adhesion molecule 1 concentrations, intracellular adhesion molecule 1 concentrations, interleukin-6 concentrations at pre-intervention (0h) and post-intervention (7h) | — |
Countries
England, United Kingdom
Contacts
Public ContactJoseph Jenkins
Outcome results
None listed